Bio-Rad Laboratories Class A
About: Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (56% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (44% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (42% of 2023 sales), Europe (31%), Asia (31%), and other (6%). Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
Employees: 8,030
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
40% more call options, than puts
Call options by funds: $6.52M | Put options by funds: $4.65M
15% more capital invested
Capital invested by funds: $5.47B [Q2] → $6.3B (+$827M) [Q3]
9% less first-time investments, than exits
New positions opened: 67 | Existing positions closed: 74
2% less funds holding
Funds holding: 432 [Q2] → 425 (-7) [Q3]
2.94% less ownership
Funds ownership: 85.48% [Q2] → 82.54% (-2.94%) [Q3]
17% less funds holding in top 10
Funds holding in top 10: 6 [Q2] → 5 (-1) [Q3]
21% less repeat investments, than reductions
Existing positions increased: 130 | Existing positions reduced: 164
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
RBC Capital Conor McNamara 26% 1-year accuracy 10 / 39 met price target | 47%upside $481 | Outperform Maintained | 9 Dec 2024 |
Citigroup Patrick Donnelly 43% 1-year accuracy 13 / 30 met price target | 37%upside $450 | Buy Maintained | 31 Oct 2024 |
Financial journalist opinion
